Eupraxia Pharmaceuticals Inc
NASDAQ:EPRX
Balance Sheet
Balance Sheet Decomposition
Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
Balance Sheet
Eupraxia Pharmaceuticals Inc
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
4
|
1
|
1
|
0
|
21
|
25
|
19
|
33
|
|
| Cash |
4
|
1
|
1
|
0
|
21
|
25
|
19
|
33
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
9
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Current Assets |
5
|
2
|
3
|
1
|
31
|
25
|
20
|
34
|
|
| PP&E Net |
0
|
0
|
1
|
0
|
1
|
1
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
1
|
0
|
1
|
1
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
6
N/A
|
3
-50%
|
3
+13%
|
1
-56%
|
31
+2 053%
|
26
-17%
|
20
-22%
|
35
+72%
|
|
| Liabilities | |||||||||
| Accounts Payable |
0
|
2
|
2
|
3
|
2
|
4
|
4
|
3
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
11
|
17
|
18
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
10
|
0
|
|
| Other Current Liabilities |
0
|
2
|
2
|
2
|
0
|
0
|
5
|
0
|
|
| Total Current Liabilities |
1
|
14
|
21
|
23
|
2
|
4
|
19
|
3
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
9
|
10
|
0
|
0
|
|
| Minority Interest |
1
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
|
| Other Liabilities |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
14
N/A
|
21
+50%
|
23
+8%
|
11
-52%
|
13
+20%
|
18
+39%
|
2
-91%
|
|
| Equity | |||||||||
| Common Stock |
24
|
24
|
24
|
24
|
81
|
92
|
93
|
148
|
|
| Retained Earnings |
20
|
40
|
47
|
51
|
74
|
97
|
106
|
131
|
|
| Additional Paid In Capital |
3
|
5
|
6
|
6
|
14
|
18
|
18
|
21
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
|
| Total Equity |
6
N/A
|
11
N/A
|
18
-60%
|
21
-20%
|
20
N/A
|
13
-37%
|
2
-83%
|
33
+1 407%
|
|
| Total Liabilities & Equity |
6
N/A
|
3
-50%
|
3
+13%
|
1
-56%
|
31
+2 053%
|
26
-17%
|
20
-22%
|
35
+72%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
13
|
13
|
13
|
13
|
14
|
22
|
27
|
36
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
|